A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Methylprednisolone (Primary) ; Prednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH-1
- Sponsors Incyte Corporation
- 15 Feb 2018 According to an Incyte Corporation media release, the Company expects to submit an sNDA seeking approval of ruxolitinib in this indication.
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Dec 2017 According to an Incyte Corporation media release, the first patient has been treated in this trial.